



Kaiser Foundation Health Plan of Washington Kaiser Foundation Health Plan of Washington Options, Inc. Provider Communications, RCR-A3W-04 PO Box 34262, Seattle WA 98124-1262

March 31, 2025

## DAXIBOTULINUMTOXINA-LANM (DAXXIFY) UPDATED PRIOR AUTHORIZATION CRITERIA

Dear Provider.

Daxibotulinumtoxina-lanm (Daxxify) is on the **non-Medicare** list of office-administered drugs requiring prior authorization. **Effective June 1, 2025**, the criteria for Daxxify will be updated to include a quantity limit. **This letter is a notification of the upcoming change in prior authorization criteria required before administering this medication in a physician's office.** 

Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington, Options, Inc. (Kaiser Permanente) requires prior authorization for a select group of injectable drugs that may be administered under the medical benefit in a physician's office or by home infusion. These reviews are intended to ensure consistent benefit adjudication as well as appropriate utilization in accordance with the Kaiser Permanente Pharmacy & Therapeutics Committee's evidence-based criteria for coverage.

Prior Authorization Criteria for Daxxify (changes are in bold):

DRUG NAME	COVERAGE CRITERIA
DAXIBOTULINUMTOXINA- LANM	Covered for adult patients who meet the following criteria:  • Diagnosis of cervical dystonia
	Quantity Limit: Max of 1 treatment every 12 weeks

## **Additional Information**

A complete list of office-administered injectable drugs requiring prior authorization can be found on the Kaiser Permanente provider website at

https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/officeinject.

To request prior authorization review, please use the Referral Request online form (login required) located on the Kaiser Permanente provider website. You can also fax your request to the Review Services department toll-free at 1-888-282-2685.

Thank you for the care you provide to our members, your patients. If you have any questions about this process, please call Review Services at 1-800-289-1363, Monday through Friday from 8 a.m. to 5 p.m.

Sincerely,

Ravi Ubriani, MD, Chair

Pharmacy & Therapeutics Committee